Amiodarone Interactions

Moderate dual CYP3A4 and CYP2C9 inhibitor may increase macitentan exposure. Avoid co-administration.

Source: NLP:macitentan

Co-administration contraindicated due to potential for cardiac arrhythmias.

Source: NLP:nirmatrelvir and ritonavir

Concomitant administration can affect conduction and repolarization and is not recommended.

Source: NLP:propafenone hydrochloride

Class III antiarrhythmic; potential to prolong refractoriness. Not recommended as concomitant therapy with sotalol.

Source: NLP:sotalol hydrochloride

Avoid use; may prolong QT interval and increase risk of arrhythmias with anagrelide.

Source: NLP:anagrelide

Avoid concomitant use due to QT prolongation risk.

Source: NLP:anagrelide hydrochloride

Antiarrhythmic with negative chronotropic properties that may be additive to those of beta-blockers.

Source: NLP:atenolol

Antiarrhythmic with negative chronotropic properties that may be additive to beta-blocker effects, increasing bradycardia risk.

Source: NLP:atenolol and chlorthalidone

As a CYP2C9 inhibitor, amiodarone combined with a strong or moderate CYP3A inhibitor will likely lead to large increases in bosentan plasma concentrations.

Source: NLP:bosentan

CYP2C9 and P-glycoprotein inhibitor increases S(-)-enantiomer concentrations at least 2-fold, enhancing beta-blocking activity and potentially slowing heart rate.

Source: NLP:carvedilol

May increase carvedilol levels resulting in further slowing of heart rate or cardiac conduction.

Source: NLP:carvedilol phosphate

Increased risk of inducing ventricular arrhythmias when used concomitantly with chloroquine.

Source: NLP:chloroquine phosphate

Antiarrhythmic affected by clarithromycin CYP3A inhibition. Risk of QTc prolongation and arrhythmias.

Source: NLP:clarithromycin

Increased pulmonary toxicity may result from combined effect with cyclophosphamide.

Source: NLP:cyclophosphamide

Increases digoxin serum concentration by 70%. Requires monitoring and dose reduction of 30-50%.

Source: NLP:digoxin

Class III anti-arrhythmic drug that may increase risk of QT prolongation and Torsades de Pointes due to additive effects on heart rate and QT interval.

Source: NLP:etrasimod

Do not exceed 10 mg/20 mg ezetimibe and simvastatin tablets daily due to increased myopathy risk.

Source: NLP:ezetimibe and simvastatin

Amiodarone may increase plasma flecainide levels two-fold or more in some patients, requiring flecainide dosage reduction.

Source: NLP:flecainide acetate

Concomitant administration may increase QT prolongation, particularly with high-dose fluconazole (800 mg). Caution required if concomitant use necessary.

Source: NLP:fluconazole

Should be avoided due to risk of QT prolongation and torsades de pointes.

Source: NLP:foscarnet sodium

May decrease or increase thyroid hormone secretion, resulting in hypothyroidism or hyperthyroidism; slowly excreted producing prolonged effects.

Source: NLP:levothyroxine sodium

Cardiac effects may be additive or antagonistic and toxic effects may be additive when administered with lidocaine.

Source: NLP:lidocaine hydrochloride

Increases risk of myopathy/rhabdomyolysis when used with HMG-CoA reductase inhibitors like lovastatin.

Source: NLP:lovastatin

Moderate dual CYP3A4 and CYP2C9 inhibitor predicted to increase macitentan exposure. Avoid concomitant use.

Source: NLP:macitentan and tadalafil

Reduction in exposure to amiodarone and its metabolite observed when coadministered.

Source: NLP:orlistat

Increases risk of myopathy and rhabdomyolysis. Do not exceed simvastatin 20 mg daily.

Source: NLP:simvastatin

P-gp inhibitor that increases talazoparib concentrations; avoid coadministration or reduce talazoparib dose and monitor for increased adverse reactions.

Source: NLP:talazoparib

Class III antiarrhythmic that prolongs QTc interval. Concomitant use should be avoided due to additive QTc prolongation risk.

Source: NLP:tetrabenazine

CYP1A2 inhibitor antiarrhythmic; concomitant use should be avoided due to potential for hypotension, bradycardia, or excessive drowsiness.

Source: NLP:tizanidine

Concomitant use should be avoided due to potential interactions. If clinically necessary, initiate with 2 mg and titrate cautiously.

Source: NLP:tizanidine hydrochloride

Should be avoided due to CYP1A2 inhibition. If necessary, initiate tizanidine at 2 mg and titrate cautiously; monitor for hypotension, bradycardia, or excessive drowsiness.

Source: NLP:tizanidne hydrochloride

CYP2C9 inhibitor that increases warfarin effect and INR; requires close INR monitoring

Source: NLP:warfarin

CYP2C9 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.

Source: NLP:warfarin sodium

Increases cyclosporine concentrations. Dosage adjustment essential.

Source: NLP:cyclosporine

CYP2C9 inhibitor may increase dronabinol systemic exposure and adverse reactions; monitor for increased dronabinol-related effects.

Source: NLP:dronabinol

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Source: NLP:fosphenytoin sodium

Class 3 antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Source: NLP:haloperidol decanoate

Class 3 antiarrhythmic that prolongs QTc interval; caution advised when used with haloperidol due to risk of QT prolongation.

Source: NLP:haloperidol lactate

Negative chronotrope that increases risk of bradycardia with ivabradine. Monitor heart rate.

Source: NLP:ivabradine

Class III antiarrhythmic drug; specific interaction studies not performed but caution is advised when used with lidocaine and prilocaine.

Source: NLP:lidocaine and prilocaine

CYP3A4 substrate whose plasma levels may increase with concomitant metronidazole use. Monitor plasma concentrations.

Source: NLP:metronidazole

P-glycoprotein inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.

Source: NLP:naldemedine

CYP2C9 inhibitor that may increase blood-glucose-lowering effect and susceptibility to hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Source: NLP:nateglinide

Moderate CYP3A4 inhibitor that may increase nimodipine plasma concentration and blood pressure lowering effect. Blood pressure monitoring and dose reduction of nimodipine may be necessary.

Source: NLP:nimodipine

α-adrenergic blocking agent that blocks phenylephrine and is blocked by phenylephrine.

Source: NLP:phenylephrine hci

α-adrenergic blocking agent that blocks phenylephrine and is blocked by phenylephrine.

Source: NLP:phenylephrine hydrochloride

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Source: NLP:extended phenytoin sodium

CYP2D6 substrate/inhibitor that may increase blood levels and/or toxicity of propranolol.

Source: NLP:propranolol hydrochloride

Amiodarone increases quinidine levels by unknown pharmacokinetic mechanisms.

Source: NLP:quinidine gluconate

Increases quinidine levels by pharmacokinetic mechanisms not well understood.

Source: NLP:quinidine sulfate tablet

Potent P-gp inhibitor that may increase rimegepant exposure. Avoid another dose within 48 hours when co-administered.

Source: NLP:rimegepant sulfate

Class III antiarrhythmic drug; specific interaction studies not performed but caution is advised.

Source: NLP:ropivacaine hydrochloride

Drug that interferes with accumulation of radioiodide by the thyroid. Discontinue 6 months before procedure.

Source: NLP:sodium iodide i 131

Amiodarone is an inhibitor of CYP2C9 and CYP3A4 likely to substantially increase systemic exposure of terbinafine when concomitantly administered.

Source: NLP:terbinafine

As a CYP2C9 and CYP3A4 inhibitor, likely to substantially increase terbinafine systemic exposure similar to fluconazole.

Source: NLP:terbinafine hydrochloride

As a CYP2C9 and CYP3A4 inhibitor, amiodarone may substantially increase systemic exposure of terbinafine (Cmax and AUC).

Source: NLP:terbinafine tablets 250 mg

CYP2C9 inhibitor that decreases torsemide clearance and increases plasma concentrations; monitor diuretic effect and blood pressure.

Source: NLP:torsemide

In vitro data of benzodiazepines suggest possible drug interaction with triazolam. Caution recommended.

Source: NLP:triazolam

P-gp inhibitor that does not require dosage adjustment of dabigatran etexilate.

Source: NLP:dabigatran etexilate